The groundbreaking success of Sildenafil undeniably revolutionized the medication landscape, but investing in companies strongly reliant on off-patent versions presents a complex picture. Although early profits were significant, the expiration of patents and the rise of discounted alternatives have diminished market share. Consequently, a thorough